2024
Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Sukumar J, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover D, Gatti‐Mays M, Pariser A, Sudheendra P, George M, Lustberg M. Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer. Cancer Medicine 2024, 13: e7317. PMID: 38895891, PMCID: PMC11185945, DOI: 10.1002/cam4.7317.Peer-Reviewed Original ResearchConceptsOvarian suppressionEndocrine therapyAdjuvant endocrine therapyBreast cancerClinicopathological featuresAromatase inhibitorsOS useHR+/HER2+ breast cancerOptimal adjuvant endocrine therapyHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Real-world treatment patternsCohort of premenopausal womenAnti-HER2 therapyPremenopausal breast cancerClinicopathological risk factorsMultivariable logistic regression assessed associationsLogistic regression assessed associationsPremenopausal BCPrescribed tamoxifenPremenopausal patientsPremenopausal womenBC subtypesContemporary cohortAnti-HER2
2023
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi C, Ruddy K, Cathcart-Rake E, Trovato S, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients. Supportive Care In Cancer 2023, 31: 717. PMID: 37991653, DOI: 10.1007/s00520-023-08160-0.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAlopeciaBreast NeoplasmsCyclin-Dependent Kinase 4FemaleHumansMinoxidilRetrospective StudiesTreatment OutcomeConceptsBreast cancer patientsTherapeutic responseAdverse eventsClinical characteristicsCancer patientsCommon cutaneous adverse eventsCutaneous adverse eventsPoor systemic absorptionRetrospective cohort studyComparison of pretreatmentEIA patientsEndocrine monotherapyClinical improvementCohort studyRetrospective cohortOncologic treatmentTopical antiandrogenCombination therapySystemic absorptionAndrogenetic alopeciaDean scaleMethodsThis studyPatientsAlopeciaScore gradeClinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Nagaraj G, Vinayak S, Khaki A, Sun T, Kuderer N, Aboulafia D, Acoba J, Awosika J, Bakouny Z, Balmaceda N, Bao T, Bashir B, Berg S, Bilen M, Bindal P, Blau S, Bodin B, Borno H, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman L, Flora D, Friese C, Galsky M, Gonzalez C, Grivas P, Gupta S, Haynam M, Heilman H, Hershman D, Hwang C, Jani C, Jhawar S, Joshi M, Kaklamani V, Klein E, Knox N, Koshkin V, Kulkarni A, Kwon D, Labaki C, Lammers P, Lathrop K, Lewis M, Li X, de Lima Lopes G, Lyman G, Makower D, Mansoor A, Markham M, Mashru S, McKay R, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen R, Nonato T, O'Connor T, Panagiotou O, Park K, Patel J, Patel K, Peppercorn J, Polimera H, Puc M, Rao Y, Razavi P, Reid S, Riess J, Rivera D, Robson M, Rose S, Russ A, Schapira L, Shah P, Shanahan M, Shapiro L, Smits M, Stover D, Streckfuss M, Tachiki L, Thompson M, Tolaney S, Weissmann L, Wilson G, Wotman M, Wulff-Burchfield E, Mishra S, French B, Warner J, Lustberg M, Accordino M, Shah D. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study. ELife 2023, 12: e82618. PMID: 37846664, PMCID: PMC10637772, DOI: 10.7554/elife.82618.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCohort StudiesCOVID-19FemaleHumansMiddle AgedRetrospective StudiesSARS-CoV-2United StatesConceptsCOVID-19 severityWorse COVID-19 outcomesCOVID-19 outcomesBreast cancerCause mortalityCohort studyAcute respiratory syndrome coronavirus 2 infectionCOVID-19Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionRegistry-based retrospective cohort studyHistory of BCIntensive care unit admissionNon-Hispanic white patientsSyndrome coronavirus 2 infectionWorse ECOG performance statusMultivariable ordinal logistic regression modelsCare unit admissionCoronavirus 2 infectionECOG performance statusRetrospective cohort studyPacific Islander patientsCoronavirus disease 2019American Cancer SocietyLogistic regression modelsResearch grant supportRetrospective cohort study of scalp cooling in breast cancer patients
Rose L, Schnell P, Radcliff L, Lustberg M, Dulmage B. Retrospective cohort study of scalp cooling in breast cancer patients. Supportive Care In Cancer 2023, 31: 118. PMID: 36645520, DOI: 10.1007/s00520-022-07562-w.Peer-Reviewed Original ResearchConceptsScalp coolingChemotherapy regimenPatient ageInsurance statusRetrospective cohort studyCommon side effectsRetrospective chart reviewNon-white patientsBreast cancer patientsStage of cancerQuality of lifeChart reviewCohort studyWhite patientsPatient's likelihoodChemotherapy infusionCancer patientsTreatment optionsOncology settingBreast cancerPatient decisionSide effectsPatientsTreatment planHealthcare providers
2021
Examining the Association of Billed Advance Care Planning With End-of-Life Hospital Admissions Among Advanced Cancer Patients in Hospice
Prater LC, O’Rourke B, Schnell P, Xu W, Li Y, Gustin J, Lockwood B, Lustberg M, White S, Happ MB, Retchin SM, Wickizer TM, Bose-Brill S. Examining the Association of Billed Advance Care Planning With End-of-Life Hospital Admissions Among Advanced Cancer Patients in Hospice. American Journal Of Hospice And Palliative Medicine® 2021, 39: 504-510. PMID: 34427154, DOI: 10.1177/10499091211039449.Peer-Reviewed Original ResearchMeSH KeywordsAdvance Care PlanningCross-Sectional StudiesDeathHospice CareHospicesHumansNeoplasmsRetrospective StudiesTerminal CareConceptsAdvance care planningDays of lifeHospital admissionAdvanced cancerCare planningACP servicesCross-sectional retrospective cohort studySystematic advance care planningLife hospital admissionsMedical claims analysisRetrospective cohort studyAdvanced cancer patientsInpatient hospital admissionsPopulation of patientsAdvanced cancer diagnosisQuality of careHospice referralCohort studyIBM MarketScanEOL outcomesInpatient admissionsStudy criteriaCancer patientsHospice careCare preferences
2020
Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer
Paredes AZ, Hyer JM, Tsilimigras DI, Palmer E, Lustberg MB, Dillhoff ME, Cloyd JM, Tsung A, Ejaz A, Wells-Di Gregorio S, Pawlik TM. Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer. Hepato Pancreato Biliary 2020, 23: 451-458. PMID: 32843275, DOI: 10.1016/j.hpb.2020.08.002.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedHumansMedicareMental DisordersPancreatic NeoplasmsRetrospective StudiesUnited StatesConceptsCancer-specific mortalityLong-term outcomesPancreatic cancerMental illnessPre-existing mental illnessSchizophrenic disordersHigh riskMedicare beneficiariesCancer-directed surgerySEER-Medicare databasePre-existing historyAnxiety/depressionEarly-stage cancerCause mortalityMultivariable analysisPancreatic adenocarcinomaStage cancerPsychotic disordersPatientsBipolar disorderIllnessCancerMortalityDisordersDepressionPalliative Care Referral Patterns for Adolescent and Young Adult Patients at a Comprehensive Cancer Center
Lockwood BJ, Ntukidem OL, Ehrman SE, Schnell PM, Klemanski DL, Bhatnagar B, Lustberg M. Palliative Care Referral Patterns for Adolescent and Young Adult Patients at a Comprehensive Cancer Center. Journal Of Adolescent And Young Adult Oncology 2020, 10: 109-114. PMID: 32706607, DOI: 10.1089/jayao.2020.0081.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentHumansMedical OncologyNeoplasmsPalliative CareReferral and ConsultationRetrospective StudiesYoung AdultConceptsPalliative careReferral patternsHigh symptom burdenRetrospective chart reviewYoung adult patientsComprehensive cancer centerEligible patientsSpecific cancer typesAdult patientsChart reviewSymptom burdenOncologic treatmentCancer CenterLung cancerInpatient settingPoor survivalCancer typesPatientsYoung adultsCancerGreater penetranceSmall percentageAdolescentsValuable rolePC access
2018
Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction
Milks M, Velez M, Mehta N, Ishola A, Van Houten T, Yildiz V, Reinbolt R, Lustberg M, Smith S, Orsinelli D. Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction. The American Journal Of Cardiology 2018, 121: 867-873. PMID: 29454478, DOI: 10.1016/j.amjcard.2017.12.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnthracyclinesAntibiotics, AntineoplasticAntineoplastic Agents, ImmunologicalAtrial FibrillationAtrial FlutterBreast NeoplasmsCoronary Artery DiseaseDiabetes MellitusDoxorubicinEchocardiographyFemaleHeart FailureHumansHypertensionLogistic ModelsMiddle AgedRenal InsufficiencyReproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsStroke VolumeTrastuzumabVentricular DysfunctionConceptsCancer therapeutics-related cardiac dysfunctionGlobal longitudinal strainRisk factorsEchocardiographic variablesCardiac dysfunctionLongitudinal strainImaging assessmentCertain clinical risk factorsHeart failure risk factorsVentricular global longitudinal strainLeft ventricular longitudinal strainClinical risk factorsLV ejection fractionVentricular longitudinal strainHigh-risk groupRisk prediction toolsFailure risk factorsReceiver-operating characteristicClinical factorsEjection fractionOncologic treatmentLV functionRetrospective studyClinical variablesBreast cancer
2015
Risk factors for anthracycline-associated cardiotoxicity
Reinbolt R, Patel R, Pan X, Timmers C, Pilarski R, Shapiro C, Lustberg M. Risk factors for anthracycline-associated cardiotoxicity. Supportive Care In Cancer 2015, 24: 2173-2180. PMID: 26563179, PMCID: PMC4874738, DOI: 10.1007/s00520-015-3008-y.Peer-Reviewed Original ResearchConceptsSingle nucleotide polymorphismsAnthracycline cardiotoxicityRisk factorsAlcoholic drinks/weekFemale breast cancer patientsHigher cardiotoxicity riskDrinks/weekModerate alcohol consumptionAnthracycline-associated cardiotoxicityBreast cancer patientsCases of cardiotoxicityMajor alleleEjection fractionPediatric patientsCancer patientsCardiotoxicity riskLower riskTherapeutic strategiesAlcohol consumptionCardiotoxicityMultivariate analysisLogistic regressionPatientsGenomic predictorsSignificant correlation
2014
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Berger M, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro C, Lustberg M. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2014, 23: 2019-2024. PMID: 25519756, PMCID: PMC4804339, DOI: 10.1007/s00520-014-2556-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDexamethasoneDiphenhydramineDrug Administration ScheduleDrug HypersensitivityFamotidineFemaleHumansInfusions, IntravenousMiddle AgedNeoplasm StagingPaclitaxelPremedicationProspective StudiesRetrospective StudiesConceptsInfusion hypersensitivity reactionPaclitaxel-based chemotherapyRescue medication useBreast cancer patientsHypersensitivity reactionsPaclitaxel dosesRescue medicationMedication useSecond doseCancer patientsBreast cancerLife-threatening complicationsMajority of patientsDoses of paclitaxelProspective pilot trialUse of paclitaxelBreast cancer treatmentPrimary endpointInfusion reactionsPremedication regimenSubsequent dosesUnwanted side effectsResultsIn totalPilot trialStudy population